BMO Capital analyst Gary Nachman noted that Aquestive Therapeutics (AQST) partner Indivior lost an appeals court ruling regarding the preliminary injunction that previously prevented Dr. Reddy's (RDY) from selling its generic version of Suboxone sublingual film. While he said the decision is disappointing and surprising, and could trigger an at-risk launch by Dr. Reddy's, Nachman sees the situation as fluid and "very manageable." There is certainly a possibility Indivior and Dr. Reddy's could settle, said the analyst, who adds that ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. Nachman has an Outperform rating and $26 price target on Aquestive shares.